Clearside Biomedical, Inc. financial data

Symbol
CLSDQ on OTC
Location
Alpharetta, GA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 367% % -27%
Debt-to-equity -138% % 41%
Return On Equity 55% % -56%
Return On Assets -145% % -56%
Operating Margin -690% % -116%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,233,981 shares -93%
Common Stock, Shares, Outstanding 5,233,981 shares -93%
Entity Public Float $92,000,000 USD 44%
Common Stock, Value, Issued $78,000 USD 4%
Weighted Average Number of Shares Outstanding, Basic 5,233,981 shares 5%
Weighted Average Number of Shares Outstanding, Diluted 5,233,981 shares 5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $3,329,000 USD -57%
Research and Development Expense $13,224,000 USD -36%
General and Administrative Expense $12,670,000 USD 8.4%
Operating Income (Loss) $22,962,000 USD 6.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $5,972,000 USD 22%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $25,996,000 USD 18%
Earnings Per Share, Basic 0 USD/shares 26%
Earnings Per Share, Diluted 0 USD/shares 26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,801,000 USD -51%
Cash, Cash Equivalents, and Short-term Investments $6,800,000 USD -71%
Accounts Receivable, after Allowance for Credit Loss, Current $266,000 USD -66%
Other Assets, Current $0 USD -100%
Assets, Current $8,254,000 USD -67%
Property, Plant and Equipment, Net $2,981,000 USD -11%
Operating Lease, Right-of-Use Asset $376,000 USD -44%
Other Assets, Noncurrent $30,000 USD 0%
Assets $11,641,000 USD -60%
Accounts Payable, Current $796,000 USD -66%
Employee-related Liabilities, Current $0 USD -100%
Accrued Liabilities, Current $1,590,000 USD -44%
Liabilities, Current $2,770,000 USD -50%
Operating Lease, Liability, Noncurrent $62,000 USD -85%
Other Liabilities, Noncurrent $400,000 USD -17%
Liabilities $65,591,000 USD 2.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax $5,000 USD
Retained Earnings (Accumulated Deficit) $373,965,000 USD -7.5%
Stockholders' Equity Attributable to Parent $53,950,000 USD -55%
Liabilities and Equity $11,641,000 USD -60%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,830,000 USD 26%
Net Cash Provided by (Used in) Financing Activities $553,000 USD -104%
Net Cash Provided by (Used in) Investing Activities $9,000 USD 84%
Common Stock, Shares Authorized 26,666,666 shares -87%
Common Stock, Shares, Issued 5,233,981 shares -93%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,392,000 USD -199%
Deferred Tax Assets, Valuation Allowance $92,388,000 USD 9.9%
Operating Lease, Liability $703,000 USD -31%
Depreciation $85,000 USD 204%
Payments to Acquire Property, Plant, and Equipment $9,000 USD -84%
Property, Plant and Equipment, Gross $4,380,000 USD -0.86%
Operating Lease, Liability, Current $384,000 USD 2.9%
Deferred Tax Assets, Operating Loss Carryforwards $56,019,000 USD 6.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $7,049,000 USD -6.3%
Additional Paid in Capital $319,937,000 USD 2.2%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%